Western blottingDilution 1:1000Tissue/Cell Type Used: HeLa cell lysateImmunofluorescenceDilution 1:100Tissue/Cell Type Used: HeLa
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Immunogen type: Recombinant proteinImmunogen Species: HumanImmunogen Region: See Notes section/OtherImmunogen Description: Human recombinant ERp57 (Grp58) protein corresponding to amino acids 25 - 505 (his-tagged)
Additional Product Details:Immunogen region: Amino acids 25-505Lot Expiration/Retest Date: Expires 1 year from purchaseOther:Immunogen region: Amino acids 25-505
Purification method: Protein G purifiedProduct type: Primary antibodyAntibody structure: Whole AntibodyProtein ID: NP_005304.3
50% glycerol, 0.09% Sodium Azide
PBS pH 7.4
Derived from cell/tissue culture
Storage and Stability
Protect from light; avoid repeated freeze-thaw cycles. Store at -20 °C long-term, 2-8 °C short-term.
ERp57, also known as Glucose Regulated Protein 58 (Grp58), Hormone-Induced Protein-70 (HIP-70) and microsomal Carnitine Palmitoyltransferase, is a member of the protein disulfide isomerase family, containing two canonical CXHC tetrapeptide active site motifs (1-5). It has quite a few diverse roles. It functions as an accessory oxidoreductase involved in disulfide bond formation. In the ER, ERp57 interacts with membrane bound calnexin and soluble calreticulin (lectin chaperones) via their praline rich P-domain arms. Lectin chaperones bind nascent non-native glycoproteins, and position ERp57 to act upon the immature or misfolded glycoproteins that possess mono-glycosylated side chains. ERp57 deletion impairs posttranslational phases of influenza hema-glutinin folding, and causes accelerated release of MHC-I molecules, resulting in the coupling of sub-optimal peptides and reduced expression and stability on the cell surface . ERp57 also contains two thioredoxin active-site sequences, CGHC and an estrogen-binding domain. ERp57 is induced by both estrogen and leuteinizing-hormone-releasing hormone in the hippocampus .